|Table of Contents|

Research progress on immunotherapy for central nervous system metastasis of non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 20
Page:
3892-3896
Research Field:
Publishing date:

Info

Title:
Research progress on immunotherapy for central nervous system metastasis of non-small cell lung cancer
Author(s):
REN Xingmei; GENG Jianxiong; YU Yan
Department of Medical Oncology,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China.
Keywords:
non-small cell lung cancer; central nervous system metastasis; immunotherapy
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.20.035
Abstract:
Lung cancer is still the leading cause of cancer-related mortality in China.Non-small cell lung cancer (NSCLC) accounts for about 80%~85% of the total number of lung cancer patients.Central nervous system metastasis is the most common metastasis site and the main cause of death of NSCLC.The emergence of small molecular tyrosinase inhibitors significantly improved the quality of life and overall survival of patients with driving gene mutation.However,the overall survival of patients without driving gene mutation and patients developed drug resistance to tyrosine kinase inhibitors is still limited.With the wide application of immune checkpoint inhibitor (ICI),immunotherapy has become a new treatment method for driving gene-negative NSCLC patients.The purpose of this article is to review the progress of immunotherapy in NSCLC central nervous system metastasis and to provide new ideas for the treatment of patients with NSCLC central nervous system metastasis.

References:

［1］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
［2］ DRAGOJ M,MILOSEVIC Z,BANKOVIC J,et al.Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma ［J］.Cell Oncol (Dordr),2017,40(1):47-62.
［3］ GAVRILOVIC IT,POSNER JB.Brain metastases:epidemiology and pathophysiology ［J］.J Neurooncol,2005,75(1):5-14.
［4］ SORENSEN JB,HANSEN HH,HANSEN M,et al.Brain metastases in adenocarcinoma of the lung:frequency,risk groups,and prognosis ［J］.J Clin Oncol,1988,6(9):1474-1480.
［5］ MUJOOMDAR A,AUSTIN JH,MALHOTRA R,et al.Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma:primary tumor size,cell type,and lymph node metastases ［J］.Radiology,2007,242(3):882-888.
［6］ LI W,YU H.Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases ［J］.J Cancer Res Clin Oncol,2020,146(1):137-152.
［7］ JABLONSKA PA,BOSCH-BARRERA J,SERRANO D,et al.Challenges and novel opportunities of radiation therapy for brain metastases in non-small cell lung cancer ［J］.Cancers (Basel),2021,13(9)：2141.
［8］ SOFFIETTI R,COSTANZA A,LAGUZZI E,et al.Radiotherapy and chemotherapy of brain metastases ［J］.J Neurooncol,2005,75(1):31-42.
［9］ EICHLER AF,KAHLE KT,WANG DL,et al.EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer ［J］.Neuro Oncol,2010,12(11):1193-1199.
［10］ HSU F,DE CALUWE A,ANDERSON D,et al.EGFR mutation status on brain metastases from non-small cell lung cancer ［J］.Lung Cancer,2016,96:101-107.
［11］ IUCHI T,SHINGYOJI M,ITAKURA M,et al.Frequency of brain metastases in non-small-cell lung cancer,and their association with epidermal growth factor receptor mutations ［J］.Int J Clin Oncol,2015,20(4):674-679.
［12］ HSU F,DE CALUWE A,ANDERSON D,et al.Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations ［J］.Curr Oncol,2017,24(4):228-233.
［13］ LE RHUN E,GUCKENBERGER M,SMITS M,et al.EANO-ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up of patients with brain metastasis from solid tumours ［J］.Ann Oncol,2021,32(11):1332-1347.
［14］ VOGELBAUM MA,BROWN PD,MESSERSMITH H,et al.Treatment for brain metastases:ASCO-SNO-ASTRO guideline ［J］.J Clin Oncol,2022,40(5):492-516.
［15］ MANTOVANI C,GASTINO A,CERRATO M,et al.Modern radiation therapy for the management of brain metastases from non-small cell lung cancer:Current approaches and future directions ［J］.Front Oncol,2021,11:772789.
［16］ SINGH R,LEHRER EJ,KO S,et al.Brain metastases from non-small cell lung cancer with EGFR or ALK mutations:A systematic review and meta-analysis of multidisciplinary approaches ［J］.Radiother Oncol,2019,144:165-179.
［17］ MOYA-HORNO I,VITERI S,KARACHALIOU N,et al.Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)［J］.Ther Adv Med Oncol,2018,10:1758834017745012.
［18］ NAGANO T,TACHIHARA M,NISHIMURA Y.Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer ［J］.Curr Cancer Drug Targets,2019,19(8):595-630.
［19］ GADGEEL SM,LUKAS RV,GOLDSCHMIDT J,et al.Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic,treated brain metastases:Exploratory analyses of the phase III OAK study ［J］.Lung Cancer,2019,128:105-112.
［20］ GOLDBERG SB,GETTINGER SN,MAHAJAN A,et al.Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases:early analysis of a non-randomised,open-label,phase 2 trial ［J］.Lancet Oncol,2016,17(7):976-983.
［21］ WANG S,HU C,XIE F,et al.Use of programmed death receptor-1 and/or programmed death ligand 1 inhibitors for the treatment of brain metastasis of lung cancer ［J］.Onco Targets Ther,2020,13:667-683.
［22］ FREEMAN-KELLER M,KIM Y,CRONIN H,et al.Nivolumab in resected and unresectable metastatic melanoma:Characteristics of immune-related adverse events and association with outcomes ［J］.Clin Cancer Res,2016,22(4):886-894.
［23］ HUA C,BOUSSEMART L,MATEUS C,et al.Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab ［J］.JAMA Dermatol,2016,152(1):45-51.
［24］ TOI Y,SUGAWARA S,KAWASHIMA Y,et al.Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab ［J］.Oncologist,2018,23(11):1358-1365.
［25］ CORTELLINI A,FRIEDLAENDER A,BANNA GL,et al.Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression >/= 50% and their relationship with clinical outcomes ［J］.Clin Lung Cancer,2020,21(6):498-508.
［26］ BALDINI E,LUNGHI A,CORTESI E,et al.Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab:The Italian NSCLC expanded access program ［J］.Lung Cancer,2020,140:59-64.
［27］ HOSOYA K,FUJIMOTO D,MORIMOTO T,et al.Association between early immune-related adverse events and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors ［J］.Clin Lung Cancer,2020,21(4):e315-e328.
［28］ DONG H,STROME SE,SALOMAO DR,et al.Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion ［J］.Nat Med,2002,8(8):793-800.
［29］ TUMEH PC,HARVIEW CL,YEARLEY JH,et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance ［J］.Nature,2014,515(7528):568-571.
［30］ SELBY MJ,ENGELHARDT JJ,QUIGLEY M,et al.Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells ［J］.Cancer Immunol Res,2013,1(1):32-42.
［31］ TANG F,DU X,LIU M,et al.Anti-CTLA-4 antibodies in cancer immunotherapy:selective depletion of intratumoral regulatory T cells or checkpoint blockade［J］.Cell Biosci,2018,8:30.
［32］ RECK M,RODRIGUEZ-ABREU D,ROBINSON AG,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer ［J］.N Engl J Med,2016,375(19):1823-1833.
［33］ BORGHAEI H,PAZ-ARES L,HORN L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer ［J］.N Engl J Med,2015,373(17):1627-1639.
［34］ RITTMEYER A,BARLESI F,WATERKAMP D,et al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK):a phase 3,open-label,multicentre randomised controlled trial ［J］.Lancet,2017,389(10066):255-265.
［35］ GOLDMAN JW,CRINO L,VOKES EE,et al.P2.36:Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets) ［J］.Journal of Thoracic Oncology,2016,11(10):S238-S239.
［36］ PACHECO JM,GAO D,CAMIDGE DR.Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 >/=50%,but unanswered questions remain ［J］.Ann Transl Med,2019,7(Suppl 3):S127.
［37］ MANSFIELD AS,HERBST RS,DE CASTRO G,et al.Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases:Pooled analysis of KEYNOTE-001,010,024,and 042［J］.JTO Clin Res Rep,2021,2(8):100205.
［38］ GOLDBERG SB,SCHALPER KA,GETTINGER SN,et al.Pembrolizumab for management of patients with NSCLC and brain metastases:long-term results and biomarker analysis from a non-randomised,open-label,phase 2 trial ［J］.Lancet Oncol,2020,21(5):655-663.
［39］ GANDHI L,RODRIGUEZ-ABREU D,GADGEEL S,et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer ［J］.N Engl J Med,2018,378(22):2078-2092.
［40］ GARASSINO MC,GADGEEL S,SPERANZA G,et al.Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer:5-year outcomes from the phase 3 KEYNOTE-189 study ［J］.J Clin Oncol,2023,41(11):1992-1998.
［41］ DOVEDI SJ,ADLARD AL,LIPOWSKA-BHALLA G,et al.Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade ［J］.Cancer Res,2014,74(19):5458-5468.
［42］ CHEN L,DOUGLASS J,KLEINBERG L,et al.Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer,melanoma,and renal cell carcinoma ［J］.Int J Radiat Oncol Biol Phys,2018,100(4):916-925.
［43］ HELLMANN MD,PAZ-ARES L,BERNABE CARO R,et al.Nivolumab plus ipilimumab in advanced non-small-cell lung cancer ［J］.N Engl J Med,2019,381(21):2020-2031.
［44］ CORTINOVIS D,CHIARI R,CATINO A,et al.Italian cohort of the nivolumab EAP in squamous NSCLC:Efficacy and safety in patients with CNS metastases ［J］.Anticancer Res,2019,39(8):4265-4271.
［45］ DEBIEUVRE D,JUERGENS RA,ASSELAIN B,et al.Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer:A real-world pooled analysis of patients from France,Germany,and Canada ［J］.Lung Cancer,2021,157:40-47.
［46］ SUN L,DAVIS CW,HWANG WT,et al.Outcomes in patients with non-small-cell lung cancer with brain metastases treated with pembrolizumab-based therapy ［J］.Clin Lung Cancer,2021,22(1):58-66.
［47］ WAKUDA K,YABE M,KODAMA H,et al.Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression ［J］.Lung Cancer,2021,151:60-68.

Memo

Memo:
-
Last Update: 1900-01-01